论文部分内容阅读
哮喘治疗仍以皮质类固醇为主,但某些慢性严重哮喘通常用此药无效。环孢菌素(CS)为T细胞激活抑制剂。CS是否可改善皮质类固醇依赖性严重哮喘的肺功能,作者用随机、双盲、安慰剂对照及交叉试验进行研究。受试者标准为年龄18～65岁,第一秒用力呼气量(FEV_1)和(或)呼气流速峰值(PEFR)低于预期值75％,需以强的松5～20mg/d长期维持治疗及需加用有效辅助治疗的哮喘患者。所有受试者于4周受试前观察期吸入舒喘宁(n=30)或吸入β_2—激动剂(n=28)后FEV_1可改善20％以上者才入选。
Asthma treatment is still corticosteroid-based, but some chronic asthma is usually used with this drug is invalid. Cyclosporine (CS) is a T cell activation inhibitor. Whether CS can improve lung function in corticosteroid-dependent and severe asthma, the authors studied with randomized, double-blind, placebo-controlled and crossover trials. Subjects were aged 18-65 years with a forced expiratory volume in the first second (FEV 1) and / or peak expiratory flow (PEFR) 75% lower than expected, requiring long-term prednisone 5-20 mg / d Maintenance treatment and need to be supplemented with effective adjuvant treatment of asthma patients. All subjects were enrolled in the study, with inhaled salbutamol (n = 30) or more than 20% improvement in FEV_1 after a 4-week pretest test period or inhaled β_2-agonist (n = 28)